ClinicalTrials.gg
RecruitingNCT06250504LAPISUpdated Jul 9, 2026

Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT

A Phase 3 interventional study of APRETUDE (cabotegravir) 600 mg\3 mL and DAPIRING (Dapivirine) 25mg Vaginal Ring in HIV Infections, sponsored by Africa Health Research Institute. Recruiting at 1 site in South Africa. Open to participants aged 15 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Africa Health Research Institute · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,052
Allocation
Randomized
Ages
15 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Planned enrollment
4th of 36
2,052 · median 200
Started
2024
with 2 others
Phase 3
12 of 36
2 open now
Primary completion
2026-04
later than 7 of 12 live
Registered
31st of 36
by date
Lead sponsor
1 of 36
Africa Health Research Institute

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 4th largest by planned enrollment, is one of 3 that started in 2024, is one of 12 in phase 3, reaches primary completion later than 7 of the 12 other live ones, and was the 31st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 15 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

The goal of this hybrid (1a) Cluster Randomised Controlled Trial phase 3B trial is to evaluate the effectiveness and implementation of offering a choice of HIV Pre-Exposure Products (PrEP) through community-based sexual and reproductive health services, on PrEP uptake and retention, and population prevalence of sexually transmissible HIV amongst adolescents and young adults living in rural South Africa.

Researchers will compare adding the choice of long-acting PrEP, i.e. two monthly injectable cabotegravir (CAB LA) or dapiravine vaginal ring and HIV post exposure prophylaxis packs to daily oral PrEP integrated with community-based SRH in the 20 intervention clusters with standard of care (SoC), daily oral PrEP integrated with community-based SRH in the 20 control clusters, on uptake and retention on PrEP. We hypothesise that offering a choice of long-acting or oral PrEP and PEP within the community-based delivery of SRH services will overcome the challenges and barriers to effective use of oral daily PrEP and lead to a population-level effect on uptake and retention on PrEP and thus the prevalence of sexually transmissible HIV amongst 15-30 year olds living in rural KwaZulu-Natal, South Africa.

Read the detailed description

This is a pragmatic trial of adding in a choice of South African Health Products Registration Authority (SAHPRA) approved newer PrEP products - APRETUDE (cabotegravir) 600 mg\3 mL: DAPIRING (Dapivirine) 25mg Vaginal Ring:56/20.2.8/0979 (22/11/2022) - to the current national department of health approved oral daily PrEP with TVF/FTC (Tenofovir disoproxil/emtricitabine), Objective 1. To measure the effectiveness of the choice of oral and long-acting PrEP, including injectable (CAB LA) and vaginal ring (DapiRing), and post exposure prophylaxis (PEP) on increasing effective uptake (adoption), retention, and adherence of PrEP compared to oral PrEP in young people aged 15-30 in rural South Africa and to estimate the preliminary effect on transmissible HIV and HIV incidence.

Objective 2. To understand real-world implementation:

2.1 To explore the acceptability, appropriateness, preference, and reach of CABLA from the perspective of young people aged 15-30 and their communities in rural South Africa 2.2 To understand the feasibility, affordability, and scalability of delivering CABLA through community-based PrEP with SRH.

2.3 To identify implementation challenges and practical solutions for CABLA initiation, laboratory monitoring (e.g. RNA testing), and safe stopping within nurse-led and rural community-based clinical settings 2.4 To evaluate the safety and tolerability of CABLA compared to oral PrEP

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
15 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All young men and women aged 15-30 who are residing in the 40 administrative clusters in the study district and attend any integrated SRH/ service

Documented HIV negative test

Suitable for PrEP and/or already on PrEP

Weight > 35 kg

Understand the required dosing schedule and HIV testing.

Aware that details can be shared with a peer navigator to support their follow-up

If pregnant or breast feeding and/or planning to become pregnant participant can be offered CAB LA, if risk of acquiring HIV out weighs unknown risk of CAB LA, but must understand that safety in pregnancy or breast feeding for CAB LA has not been established and oral daily PrEP is a safe alternative.

Exclusion criteria

Exclusion Criteria:

History or presence of allergy to the study drugs or their components

Investigator assessment find them not suitable

Additional exclusion criteria for specific products:

CAB LA: Taking medication that is (Carbamazepine, oxcarbazepine, phenobarbital, phenytoin, Rifampin, rifapentine) and Severe mental health disorder, Hep B surface antigen positive, living with and not yet treated, or abnormal liver function tests ( more than two times the )

DapiRing: Pregnancy.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
2,052 participants (estimated)

Study arms

  • Experimental
    Intervention: Choice of long-acting PrEP and PEP added to Thetha Nami ngithethe nawe

    Tailored peer-led psychosocial support and social mobilisation into community based SRH and differentiated HIV care and prevention, including a choice of effective PrEP or PEP. At the mobile AYFS in the intervention clusters nurses will offer the choice of either daily oral tenofovir/emtricitabine or injectable long acting cabotegravir (CAB LA) to be delivered to adolescents and young adults at risk of HIV acquisition. Those who decline will have the option of three monthly dapivarine vaginal rings or Post Exposure Prophylaxis (PEP) packs (tenofovir/lamuvidine/dolutegravir) to take home. Peer navigators will promote long-acting PrEP in addition to oral PrEP. As part of the peer mentorship package, the peer naviators will remind young people of their follow-up visits.

    Drug: APRETUDE (cabotegravir) 600 mg\3 mL · Drug: DAPIRING (Dapivirine) 25mg Vaginal Ring · Drug: tenofovir disoproxil and emtricitabine · Drug: Tenofovir Disoproxil, Lamuvidine and Dolutegravir

  • Active comparator
    Control (Enhanced SoC): Thetha Nami ngithethe nawe

    Tailored peer-led psychosocial support and social mobilisation into community based SRH and differentiated HIV care and prevention, including oral tenofovir/emtricitabine PrEP. In the mobile AYFS, young people are offered self-taken vaginal swabs or urine testing for sexually transmitted infections (STIs), family planning support and syndromic and aetiological management for STIs; HIV counselling and two POCT; immediate initiation of ART if living with HIV and oral tenofovir/emtricitabine PrEP if HIV test is negative and they are suitable. Peer navigators in control clusters will promote oral PrEP during their community based health promotion activities. As part of the peer mentorship package, the peer naviators will remind young people of their follow-up visits and if required accompany young people to the mobile clinics.

    Drug: tenofovir disoproxil and emtricitabine

Interventions

  • DrugCabotegravirStudies of CabotegravirCabotegravir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    choice of 2-monthly injectable long acting cabotegravir. The initial visit will be followed by planned visit for the first injection, one month visit for second injection, and then 2-monthly CAB LA injections with repeat HIV testing and pregnancy testing, and referral to peer navigators for adherence and retention support. We will conduct HIV testing, STI testing, Hep B, Hep C, and safety bloods (Full Blood Count, Creatinine, Liver Function Tests) at baseline, HIV testing two monthly, and annual safety bloods, alongside annual STI testing.

  • DrugDapivirineStudies of DapivirineDapivirine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing

  • Drugtenofovir disoproxil and emtricitabine

    Drug pages: TenofovirStudies of TenofovirTenofovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EmtricitabineStudies of EmtricitabineEmtricitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing

  • DrugTenofovir Disoproxil, Lamuvidine and Dolutegravir

    The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing

06

What researchers measure

Primary outcomes

  1. Uptake PrEP

    Defined as the proportion of all young people (aged 15-30) residing in the trial area (the 40 clusters) who have received any PrEP (oral, injectable, ring, or PEP) through study-linked clinics

    Time frame: Through duration of trial, and up to 20 months

  2. Retention on PrEP

    Defined as the proportion of participants enrolled at least 4 months before the end of the trial, attending at least one follow-up appointment after PrEP/PEP initiation.

    Time frame: 14 months

Secondary outcomes

  1. The prevalence of transmissible HIV.

    We will measure this outcome as the proportion of those living with HIV and have a detectable HIV viral load, defined as having an HIV viral load of \>= 400 copies per ml, during our final survey round.

    Time frame: 14 months

  2. Uptake of risk informed HIV prevention

    Defined as the proportion of 15-30 year olds who are aware of their HIV status and are either on PrEP, if HIV negative, or are on antiretroviral therapy if living with HIV, during final survey round.

    Time frame: 14 months

  3. Uptake of contraception

    Proportion of women aged 15-30 who report currently using any contraception during final survey round

    Time frame: 14 months

  4. Teenage Pregnancy

    Proportion of adolescent girls aged 15-19 years who self-report currently being pregnant in the final survey round.

    Time frame: 14 months

  5. Curable Sexually Transmitted Infections

    Prevalence of any curable STIs is defined as the proportion of participants who test positive for at least one of the following infections: Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (NG), based on Cepheid GeneXpert CT/NG testing measured in the final survey round

    Time frame: 14 months

  6. Voluntary male medical circumcision (VMMC)

    Proportion of male participants who report ever having undergone circumcision in the final survey round

    Time frame: 14 months

  7. Proportion of men and women aged 16-30 at risk of acquiring HIV or transmitting HIV

    If living with HIV (a detectable viral load + condomless sex + not on ART), or, if not living with HIV (condomless sex + not on PrEP)

    Time frame: 14 months

  8. HIV incidence

    The rate of new infections in the PrEP cohort irrespective of PrEP use

    Time frame: 14 months

  9. Recent HIV infection using recency assays

    Proportion of those living with HIV in the end-line survey with a positive recency assay on DBS

    Time frame: 14 months

  10. improved mental health

    Proportion with PHQ9 score consistent with common mental disorder in each arm

    Time frame: 14 months

  11. PrEP Reach (Adoption)

    Proportion of those at greatest risk adopting (taking up) PrEP or PEP in each arm. Greatest risk is defined as an aggregate exposure disaggregated by gender that includes any of the following factors: out of school (aged \<= 18) or unemployed (aged \>18) and/or engaged in transactional sex or sex work and/or harmful alcohol use (AUDIT scale) and/or experience physical, sexual or emotional violence (validated tool) and/or food poverty (recent experience of hunger)

    Time frame: 14 months

  12. Adverse events

    frequency and severity of adverse events associated with CABLA compared to oral PrEP.

    Time frame: 14 months

  13. PrEP delivery cost and cost-effectiveness

    cost per effective PrEP uptake in each arm

    Time frame: 14 months

  14. Patterns of PrEP/PEP use

    Longitudinal patterns of PrEP and PEP initiation, switching and stopping within the choice arm

    Time frame: 14 months

Other outcomes

  1. Improved socioeconomic outcomes

    Defined as proportion in school (aged \<= 18) or unemployed (aged \>18) and/or food secure (no recent experience of hunger) in each arm.

    Time frame: 14 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Busang J, Zuma T, Chimbindi N, Ngoma N, Herbst C, Okesola N, Dreyer J, Smit T, Bird K, Mtolo L, Behuhuma N, Lebina L, Hendrickson C, Miot J, Hanekom W, Herbst K, Seeley J, Copas A, Baisley K, Shahmanesh M; LAPIS Study Team. Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation. BMC Public Health. 2026 Jan 20;26(1):610. doi: 10.1186/s12889-025-24889-1. PubMed 41559582 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After the primary analysis has been completed and publicaly shared

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2026, 26 months.

Of 44 non-industry phase 3 interventional studies under HIV Infections, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 26 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
Feb 9, 2024
StartActual
Feb 27, 2024
Primary completionActual
Apr 30, 2026
CompletionEst.
Oct 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06250504
Lead sponsor
Africa Health Research Institute
Responsible party
Sponsor
First posted
Feb 9, 2024
Start date
Feb 27, 2024
Primary completion
Apr 30, 2026
Completion
Oct 2026 (estimated)
Last update
Jul 9, 2026

Study contacts

Maryam G Shahmanesh, MBBChir PhD
Contact
m.shahmanesh@ucl.ac.uk
+447776185572
Limakatso Lebina, MBBS PhD
Contact
l.lebina@ucl.ac.uk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabotegravir · Dapivirine

Start the discussion